



Curriculum Vitae

Personal information **Martin Spruth**

Work experience

1. Employer: AGES GmbH
 - Start date: 11/2018
 - End date: present
 - Position: Quality Assessor - Senior Expert
 - Activities: Quality assessment (CP, MCP/DCP, and National MAA/Variations, Clinical Trial applications) and EMA/national Scientific Advice for Biologicals including Vaccines (protein-based, glycoconjugates, inactivated, viral vector, mRNA), rDNA products, Biosimilars, and ATMPs
 - Country: Austria
2. Employer: AGES GmbH
 - Start date: 08/2015
 - End date: 10/2018
 - Position: Quality Assessor
 - Activities: Quality assessment (CP and MCP/DCP MAA/Variations, Clinical Trial applications) and EMA/national Scientific Advice for Biologicals including Vaccines (protein-based, glycoconjugates, inactivated, viral vector, mRNA), rDNA products, Biosimilars, and ATMPs
 - Country: Austria
3. Employer: Pfizer Manufacturing Austria GmbH
 - Start date: 12/2014
 - End date: 08/2015
 - Position: Head QC Orth
 - Activities: Management of QC department (Biochemistry, Separation Methods, Biological Labs, Sterility/Microbiology, and Animal Housing unit); setup and consolidation of QC department (transfer of commercial vaccine business from Baxter to Pfizer); optimisation, transfer and validation of analytical methods; QC release testing for FSME Immun and NeisVac C; microbiological environmental monitoring; member of process monitoring and local quality review boards; member of site leadership team (Orth a.d. Donau)
 - Country: Austria
4. Employer: Baxter AG
 - Start date: 01/2014
 - End date: 11/2014
 - Position: Manager QC Orth Microbiological Control
 - Activities: Management of QC Microbiological Control (Bacteriology & In Vivo Testing, Microbiology, Virology, In Vitro Testing, Sterility Testing, and Tissue Culture teams); QC release testing for investigational and market products (plasma-derived, recombinant, vaccines), microbiological environmental monitoring; optimisation, transfer and validation of biological assays; member in analytical project teams, member of process monitoring and local quality review boards
 - Country: Austria
5. Employer: Valneva Austria GmbH (former Intercell AG)
 - Start date: 02/2011
 - End date: 12/2013
 - Position: Department Head QC Clinical Serology
 - Activities: Management of QC Clinical Serology; deputy Head of QC; Analytical Project Manager and primary contact for testing services; development, transfer and validation of bioassays; GCLP compliant clinical immunology testing for viral and bacterial vaccine trials; preparation of analytical reports and submission documents; core team member in product development and clinical data evaluation teams; member of local quality review board; guest member of research & development committee
 - Country: Austria
6. Employer: Intercell AG
 - Start date: 09/2008
 - End date: 01/2011
 - Position: Function Head Clinical Serology & PRNT Laboratory
 - Activities: Management of laboratory and staff; development, transfer and validation of immunological assays incl. product release assays; GCLP/GMP compliant clinical immunology/product release testing for viral and bacterial vaccines; core team member in product development teams; preparation of technical and study reports for regulatory submission; technical expert in supplier audits; member of serological assay steering committee; member of local quality review board; acting Scientific Head of QC Intercell Biomedical Ltd, Livingston, UK (Oct 2008 - Mar 2009)
 - Country: Austria, Scotland
7. Employer: Intercell AG
 - Start date: 11/2006
 - End date: 08/2008
 - Position: Scientist Clinical Immunology
 - Activities: Development and validation of immunological assays; core team member of product development teams; GCLP/GMP compliant clinical immunology/product release testing for viral and bacterial vaccine clinical trials
 - Country: Austria
8. Employer: ViruSure GmbH
 - Start date: 03/2006
 - End date: 10/2006
 - Position: Manager Virology Testing

- Activities: Prion removal studies (contract service); virological assay development; preparation of study reports; establishment of laboratory and quality systems
 - Country: Austria
9. Employer: Baxter AG
- Start date: 01/2004
 - End date: 02/2006
 - Position: Manager Virology - Viral Vaccines
 - Activities: Management of department; preclinical development of Vero cell culture-derived viral vaccines (SARS-CoV, H5N1); bioassay development; core team member of product development teams; preparation of technical reports and submission documents
 - Country: Austria
10. Employer: Baxter AG
- Start date: 03/1999
 - End date: 12/2003
 - Position: Scientist/Manager Global Pathogen Safety - Process Development
 - Activities: GLP Study Director; planning and conduct of GLP-compliant virus clearance studies for plasma-derived and recombinant products; development and evaluation of new pathogen clearance methods; validation; training and supervision of staff; preparation of expert reports for regulatory Submission; representative of Global Pathogen Safety in product development teams
 - Country: Austria
11. Employer: Leopold-Franzens-University Innsbruck
- Start date: 09/1998
 - End date: 02/1999
 - Position: Post Doc
 - Activities: Research on neutralisation of HIV-1 by alloimmune sera in collaboration with the Institute for Blood Transfusion and the Immunological department of the public state hospital Innsbruck Virology, Immunology, Protein chemistry, Cell culture
 - Country: Austria
12. Employer: University of Applied Sciences FH Campus Wien
- Start date: WS 2017/18
 - End date: WS 2020/21
 - Position: Visiting Lecturer
 - Activities: Lectures in master studies "Bioprocess engineering" and "Biotechnological Quality Management"
 - Austria
13. Employer: IMC University of Applied Sciences Krems
- Start date: 03/2004
 - End date: 12/2007
 - Position: Visiting Lecturer
 - Activities: Lectures in degree program "Medical and Pharmaceutical Biotechnology"
 - Country: Austria
14. Employer: IMC University of Applied Sciences Krems
- Start date: 09/2004
 - End date: 10/2006
 - Position: External Member of Biological Safety Committee
 - Activities:
 - Country: Austria

Education and training

1. Subject: PhD Student, Experimental PhD thesis on "Interactions between human immunodeficiency virus type I and the humoral immune response: role of factor H and strategies for virus neutralisation", Research visit at Università di Milano, Italy, Centro Interdipartimentale L.I.T.A. Vialba (Apr 1996), Virology, Immunology, Protein chemistry, Cell culture
 - Start date: 07/1994
 - End date: 07/1998
 - Qualification: Dr. rer. nat. (equivalent to PhD)
 - Organisation: Leopold-Franzens-University Innsbruck
 - Country: Austria
2. Subject: Study of Biology with focus on Microbiology, Botany and Chemistry, Experimental Diploma thesis: "Mechanism of sodium transport by the sodium-dependent ATPase of *Acetobacterium woodii*: identification and characterisation of a cation binding site" Microbiology, Protein chemistry
 - Start date: 09/1988
 - End date: 06/1994
 - Qualification: Certified Biologist (equivalent to Master degree)
 - Organisation: Georg-August-University Göttingen
 - Country: Germany

Additional information

Publications

Spruth, M., Reidlinger, J., and Müller, V. (1995) Sodium ion dependence of inhibition of the Na⁺ translocating F1F0-ATPase from *Acetobacterium woodii*. Probing the site(s) involved in ion transport. *Biochim. Biophys. Acta* 1229: 96-102; Dierich, M.P., Frank, I., Stoiber, H., Clivio, A., Spruth, M., Steindl, F., and Katinger, H.W. (1996) The envelope of HIV. *Immunol. Lett.* 54: 205-206; Schwendinger, M.G., Spruth, M., Schoch, J., Dierich, M.P., and Proding, W.M. (1997) A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells. *J. Immunol.* 158: 5455-5463; Würzner, R., Gruber, A., Stoiber, H., Spruth, M., Chen, Y.H., Lukasser, Vogl, E., Schwendinger, M.G., and Dierich, M.P. (1997) Human Immunodeficiency Virus Type 1 gp41 binds to *Candida albicans* via complement C3-like regions. *J. Infect. Dis.* 176: 492-498; Stoiber, H., Frank, I., Spruth, M., Schwendinger, M., Müllauer, B., Windisch, J.M., Schneider, R., Katinger, H., Ando, I., and Dierich, M.P. (1997) Inhibition of HIV-1 infection in vitro by monoclonal antibodies to the complement receptor type 3 (CR3): An accessory role for CR3 during virus entry? *Mol. Immunol.* 34: 855-863; Proding, W.M., Hellwage, J., Spruth, M., Dierich, M.P., and Zipfel, P.F. (1998) The C-terminus of factor H: monoclonal antibodies inhibit heparin binding and identify epitopes common to factor H and factor H-related proteins. *Biochem. J.* 331: 41-47; Kacani, L., Frank, I., Schwendinger, M.G., Spruth, M., Müllauer, B., Sprinzl, G., Steindl, F., and Dierich, M.P. (1998) Dendritic cells transmit human immunodeficiency virus type 1 to monocytes and monocyte-derived macrophages. *J. Virol.* 72: 6671-6677; Frank, I., Kacani, L., Stoiber, H., Stössel, H., Spruth, M., Steindl, F., Romani, N. and Dierich, M.P. (1999) Human immunodeficiency virus type 1 derived from cocultures of immature dendritic cells with autologous T cells carries T-cell-specific molecules on its surface and is highly infectious. *J. Virol.* 73: 3449-3454; Spruth, M., Stoiber, H., Kacani, L., Schönitzer, D., and Dierich, M.P. (1999) Neutralization of HIV type 1 by alloimmune sera derived from polytransfused patients. *AIDS Res. Hum. Retroviruses.* 15: 533-543; Mühlbacher, M., Spruth, M., Siegel, F., Zangerle, R., and Dierich, M.P. (1999) Longitudinal study of antibody reactivity against HIV-1 envelope and a peptide representing a conserved site on Gp41 in HIV-1-infected patients. *Immunobiology* 200: 295-305; Kacani, L., Proding, W.M., Sprinzl, G.M., Schwendinger, M.G., Spruth, M.,

Stoiber, H., Döpfer, S., Steinhuber, S., Steindl, F., and Dierich, M.P. (2000) Detachment of human immuno-deficiency virus type 1 from germinal centers by blocking complement receptor type 2. *J. Virol.* 74: 7997_8002; Stoiber, H., Ammann, C., Spruth, M., Müllauer, B., Eberhart, A., Harris, CL., Huber, CG., Longhi, R., Falkensammer, B., Würzner, R., and Dierich, M.P. (2001) Enhancement of complement-mediated lysis by a peptide derived from SCR 13 of complement factor H. *Immunobiology* 203:670_686; Wilfingseder, D., Spruth, M., Ammann, C.G. Döpfer, S., Speth, C., Dierich, M.P. and Stoiber, H. (2003) Complement-mediated enhancement of HIV_1 neutralisation by anti_HLA antibodies derived from polytransfused patients. *Int. Arch. Allergy Immunol.* 131: 62_72; Gruber, A., Lell, C.P., Spruth, M., Lass_Flörl, C., Speth, C., Stoiber, H., Hube, B., Coleman, D., Polonelli, L., Dierich, M.P., and Würzner, R. (2003) HIV_1 and its transmembrane protein gp41 bind to different *Candida* species modulating adhesion. *FEMS Immunol. Med. Microbiol.* 37: 77_83; Berting, A., Görner, W., Spruth, M., Kistner, O., and Kreil, T. R. (2005) Effective poxvirus removal by sterile filtration during manufacture of plasma derivatives. *J. Med. Virol.* 75: 603_607; Spruth, M., Kistner, O., Savidis_Dacho, H., Hitter, E., Crowe, B., Gerencer, M., Brühl, P., Grillberger, L., Reiter, M., Tauer, C., Mundt, W. and Barrett, N. (2006) A double_inactivated whole virus candidate SARS Coronavirus vaccine stimulates neutralizing and protective antibody responses. *Vaccine* 24: 652_661; Kreil, T.K., Wieser, A., Berting, A., Spruth, M., Medek, C., Pölsler, G., Gaida, T., Haemmerle, T.H., Teschner, W., Schwarz, H.P., and Barrett, N. (2006) Removal of small nonenveloped viruses by antibody_enhanced nanofiltration during the manufacture of plasma derivatives. *Transfusion* 46: 1143_1151; Kistner, O., Howard, K.M. Spruth, M., Wodal, W., Brühl, P., Gerencer, M., Crowe, B., Savidis_Dacho, H., Livey, I., Reiter, Mayerhofer, I., Tauer, C., Grillberger, L., M., Mundt, W., Falkner, F.G., and Barrett, P.N. (2007) Cell culture (Vero) derived whole_virus (H5N1) vaccine based on wild_type virus strain induces cross_protective immune responses. *Vaccine* 25: 6028_6036; Pölsler, G., Berting, A., Kindermann, J., Spruth, M., Hämmerle, T., Teschner, W., Schwarz, H.P., and Kreil, T.R. (2008) A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity. *Vox Sang.* 94: 184_192; Kaltenböck, A., Dubischar-Kastner, K., Eder, G., Jilg, W., Klade, C., Kollaritsch, H., Paulke-Korinek, M., von Sonnenburg, F., Spruth, M., Tauber, E., Wiedermann, U., and Schuller, E. (2009) Safety and immunogenicity of concomitant vaccination with the cell_culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single_blind, randomized, controlled Phase 3 study. *Vaccine* 27: 4483_4489; Van Gessel, Y., Klade, C. S., Putnak, R., Formica, A., Krasaesub, S., Spruth, M., Cena, B., Tungtaeng, A., Gettayacamin, M., and Dewasthaly, S. (2011) Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO®) induced neutralizing antibody titers. *Vaccine* 29: 5925_5931; Dubischar KL, Kadlecsek V, Sablan JB, Borja_Tabora CF, Gatchalian S, Eder_Lingelbach S, Kiermayr S, Spruth M, Westritsch K. (2017) Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus_endemic Region. *Pediatr Infect Dis J.* 36(9): 898_904

Projects

Intercell AG/Valneva Austria GmbH: Development of vaccines targeting Japanese Encephalitis virus (IXIARO, Clinical Phase II - IV trials), *C. difficile*, *S. pneumoniae*, *P. aeruginosa*, *Borrelia*, seasonal Influenza (including Clinical Phase I and II trials),

Baxter AG: Development of SARS-CoV and H5N1 vaccines (sponsored by NIH), Development of an UV irradiation process for virus inactivation

Memberships

EMA Expert
 BWP ESEC Member
 BV-OEG Member
 PDA Member

Other Relevant Information